Atovaquone-d4

• UNSPSC Description:

  Atovaquone-d4 is the deuterium labeled Atovaquone. Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia[1].

• Target Antigen:

  Isotope-Labeled Compounds; Parasite

• Type:

  Isotope-Labeled Compounds

• Related Pathways:

  Anti-infection;Others

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1C2=C(C(C(O)=C1[C@@H]3CC[C@@H](C4=CC=C(Cl)C=C4)CC3)=O)C([2H])=C([2H])C([2H])=C2[2H]

• Molecular Weight:

  370.86

• References & Citations:

  [1]Looareesuwan, S., et al., Clinical studies of atovaquone, alone or in combination with other antimalarial drugs, for treatment of acute uncomplicated malaria in Thailand. Am J Trop Med Hyg, 1996. 54(1): p. 62-6.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2070015-14-2